Table 1 Univariate analysis of clinical features and response to pyrotinib combined with trastuzumab (HP) treatment.

From: PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer

Marker

pCR no. (%)

Non-pCR no. (%)

ORa (95% CI)

Pb

Age

   

0.485

 <40

5 (45.5)

6 (54.5)

  

 ≥40

21 (61.8)

13 (38.2)

1.91 (0.39−9.72)

 

Menstrual status

   

1.000

 Premenopausal

17 (56.7)

13 (43.3)

  

 Menopausal

9 (60.0)

6 (40.0)

1.14 (0.28−4.99)

 

Lymph node

   

0.054

 Positive

14 (46.7)

16 (53.3)

  

 Negative

12 (80.0)

3 (20.0)

4.42 (0.93−29.4)

 

Clinical stage

   

0.039

 I–II

18 (72.0)

7 (28.0)

  

 III

8 (40.0)

12 (60.0)

0.27 (0.06−1.06)

 

Hormone receptor

   

0.071

 Positive

10 (43.5)

13 (56.5)

  

 Negative

16 (72.7)

6 (27.3)

3.37 (0.85−14.75)

 

HER2

    

 2+, FISH+ 

1 (16.7)

5 (83.3)

 

0.069

 3+

25 (64.1)

14 (35.9)

8.51 (0.83−437.6)

 

Ki67

   

1.000

 ≤30

15 (57.7)

11 (42.3)

  

 >30

11 (57.9)

8 (42.1)

1.01 (0.26−3.97)

 

TILs

   

0.078

 Low

4 (30.8)

9 (69.2)

  

 Intermediate

19 (67.9)

9 (32.1)

–

 

 High

3 (75.0)

1 (25.0)

–

 
  1. pCR pathologic complete response, OR odds ratio, CI confidence interval, HER2 human epidermal growth factor receptor 2, FISH fluorescence in situ hybridisation, TILs tumour-infiltrating lymphocytes.
  2. aThe conditional maximum likelihood estimate (MLE) of the odds ratio was used.
  3. bP value calculated using a Fisher’s exact test.
Back to article page